Arianne Bennett-Venner, MD
Pulmonary Disease · Orange City, FLNPI 1205084175
Payments from drug & device makers
Across 259 payments — averaging $22.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$1K
- Boehringer Ingelheim$790
- Grifols USA, LLC$537
- Sanofi$293
- Regeneron Healthcare Solutions, Inc.$254
- plus $2K from 24 others
What the payments were for
- Food & beverage$5,79399%
- Education$691%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 39 | $1,083 |
| GSK | 81 | $1,014 |
| Boehringer Ingelheim | 36 | $790 |
| Grifols USA, LLC | 15 | $537 |
| Sanofi | 6 | $293 |
| Regeneron Healthcare Solutions, Inc. | 6 | $254 |
| Mallinckrodt Hospital Products Inc. | 5 | $193 |
| Harmony Biosciences LLC | 6 | $180 |
| Pulmonx Corporation | 3 | $157 |
| Jazz Pharmaceuticals Inc. | 4 | $141 |
| Sunovion Pharmaceuticals Inc. | 10 | $133 |
| Johnson & Johnson | 1 | $123 |
| Insmed, Inc. | 6 | $120 |
| Inspire Medical Systems, Inc. | 1 | $120 |
| Mylan Specialty L.p. | 5 | $116 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $81 |
| Teva Pharmaceuticals USA, Inc. | 4 | $65 |
| Inogen, Inc. | 5 | $62 |
| Electromed, Inc. | 5 | $58 |
| Merck | 3 | $52 |
| Actelion Pharmaceuticals US, Inc. | 2 | $47 |
| Shire North American Group Inc | 3 | $47 |
| Genentech USA, Inc. | 2 | $36 |
| Covis Pharma GmbH | 2 | $30 |
| Inari Medical, Inc. | 1 | $30 |
| ANI Pharmaceuticals, Inc. | 1 | $24 |
| La Jolla Pharmaceutical Company | 1 | $21 |
| Biomerieux Inc | 1 | $21 |
| Pfizer | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$467
- Prolastin-C Liquid$163
- Xembify$158
- TEZSPIRE$135
- FASENRA$130
- ACTHAR$125
- BREZTRI AEROSPHERE$125
- TAGRISSO$124
- Monarch Platform$123
- Inspire Upper Airway Stimulation System$120
- CHARTIS CATHETER$116
- ZEPHYR DELIVERY CATHETER$116
- ZEPHYR ENDOBRONCHIAL VALVE$116
- PULMONX CHARTIS TABLET CONSOLE$116
- OFEV$104
How this compares
$5,862 in reported general payments places this provider in the 55th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 344 | $237,589 |
| Dupixent PenDupilumab | 12 | $44,906 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 30 | $27,421 |
| Breo ElliptaFluticasone/Vilanterol | 57 | $24,787 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 132 | $16,188 |
| Spiriva RespimatTiotropium Bromide | 27 | $14,586 |
| EliquisApixaban | 14 | $13,058 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $6,542 |
| Arnuity ElliptaFluticasone Furoate | 17 | $4,693 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 202 | $4,307 |
| Roflumilast | 22 | $2,870 |
| BreynaBudesonide/Formoterol Fumarate | 15 | $2,571 |
| Wixela InhubFluticasone Propion/Salmeterol | 24 | $1,909 |
| Montelukast Sodium | 225 | $1,731 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $1,291 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,014 | $267,069418 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,083 | $33,96348 claims |
| Boehringer IngelheimSpiriva Respimat | $790 | $14,58627 claims |
| PfizerEliquis | $19 | $13,05814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Orange City
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
- Leonard DunnDunedin$7.6M
- Francis AverillClearwater$6.3M
- Charles BurgerJacksonville$5.6M
- Daniel LorchBrandon$5.5M
- Lourdes BoschMiami$4.2M
- Raj KarunakaraOcala$4M
- Neal WarshoffLoxahatchee$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.